아이카디 구티에레스 증후군 : 시장 인사이트, 역학, 시장 예측(2034년)

Key Highlights:

• The Aicardi Goutieres Syndrome market is projected to witness consistent growth throughout the forecast period (2024-2034). The Aicardi Goutieres Syndrome market size in the 7MM is expected to increase, driven by better diagnosis and the launch of emerging therapies.
• DelveInsight's analysis estimates that among the total diagnosed prevalent cases of Aicardi Goutieres Syndrome in 7MM approximately 48% of cases were from the US. As per our estimations, in 2023, the US accounted for nearly 411 diagnosed prevalent cases of Aicardi Goutieres Syndrome.
• The total Aicardi Goutieres Syndrome market size is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, TPN-101.
• The Aicardi Goutieres Syndrome market for therapeutics targeting Aicardi Goutieres Syndrome is projected to experience robust growth, at a significant compound annual growth rate (CAGR) from 2024 to 2034. This dynamic expansion reflects increasing demand for advanced treatment options and underscores the growing investment in addressing this serious condition.
• In May 2023, the Aicardi Goutieres Syndrome Advocacy Association (Aicardi Goutieres SyndromeAA) and Transposon Therapeutics, Inc. announced a strategic collaboration aimed at revolutionizing the approach to treating Aicardi Goutieres Syndrome. This partnership focuses on integrating patient perspectives into trial design, enhancing recruitment strategies, and broadening educational efforts about novel therapies. By prioritizing patient needs and inclusivity, this initiative not only promises to refine therapeutic development but also sets a new standard for patient-centered research in rare diseases.

The Aicardi Goutieres Syndrome market is shaped by several critical factors, including the increasing prevalence of genetic disorders and heightened awareness about rare diseases. Advances in genomic research and growing investments in rare disease therapies are driving market growth. Nonetheless, challenges such as limited funding for research, high costs of novel treatments, and rigorous regulatory hurdles remain significant obstacles. Moreover, the substantial unmet need for effective Aicardi Goutieres Syndrome treatments underscores a major gap in the current therapeutic landscape, presenting a prime opportunity for companies to innovate and address the needs of a diverse patient population.

DelveInsight's "Aicardi Goutieres Syndrome Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Aicardi Goutieres Syndrome, historical and forecasted epidemiology and the Aicardi Goutieres Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Aicardi Goutieres Syndrome market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Aicardi Goutieres Syndrome market size from 2020 to 2034. The report also covers current Aicardi Goutieres Syndrome treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Aicardi Goutieres Syndrome Treatment Market

Aicardi Goutieres Syndrome Overview

Aicardi Goutieres Syndrome is a rare genetic disorder that primarily affects the brain, immune system, and skin. It is characterized by the early onset of neurological symptoms, including developmental delay, intellectual disability, motor abnormalities, and severe cognitive impairment. The syndrome often manifests in infancy or early childhood, with symptoms progressively worsening over time.

The underlying cause of Aicardi Goutieres Syndrome is linked to mutations in specific genes involved in the immune response and DNA repair. These genetic mutations lead to abnormal activation of the immune system, resulting in neuroinflammation and damage. Environmental factors, such as viral infections during pregnancy, may also contribute to the onset of Aicardi Goutieres Syndrome. However, Aicardi Goutieres Syndrome is not directly associated with lifestyle factors or alcohol consumption.

Symptoms of Aicardi Goutieres Syndrome typically become apparent within the first year of life and can include irritability, poor feeding, seizures, and developmental regression. As the disease progresses, affected individuals may experience severe cognitive impairment, motor dysfunction, skin rashes, and other systemic issues. Early diagnosis and intervention are crucial for managing symptoms and improving the quality of life for those affected by Aicardi Goutieres Syndrome.

Aicardi Goutieres Syndrome Diagnosis

Diagnosing Aicardi-Goutieres Syndrome involves a comprehensive approach that includes a thorough patient history, clinical evaluation, and supportive diagnostic tests. While no single test confirms Aicardi Goutieres Syndrome, a combination of genetic testing and imaging studies is used to support the diagnosis. Key diagnostic tools include brain imaging (such as MRI or CT scans) to identify characteristic neurological changes, and cerebrospinal fluid (CSF) analysis to detect inflammation and other abnormalities. Genetic testing is crucial to confirm mutations in genes associated with Aicardi Goutieres Syndrome, as these provide definitive evidence of the condition.

In addition to these tests, clinicians may perform a range of blood tests to assess immune function and rule out other conditions. Given the complexity of Aicardi Goutieres Syndrome and its overlap with other neurological disorders, an accurate diagnosis often requires collaboration among specialists, including neurologists, geneticists, and immunologists. Early and precise diagnosis is essential for managing symptoms and tailoring treatment strategies to improve patient outcomes and quality of life.

Aicardi Goutieres Syndrome Treatment

Managing Aicardi Goutieres Syndrome requires a comprehensive and personalized approach to address its diverse symptoms and progression. Since there is no cure for Aicardi Goutieres Syndrome, treatment primarily focuses on alleviating symptoms and enhancing quality of life. Symptomatic treatment plays a key role, including medications to manage neurological symptoms such as seizures and muscle spasms.

Supportive therapies, including physical, occupational, and speech therapy, are crucial for maintaining motor skills, cognitive function, and communication abilities. Immunomodulatory treatments, such as interferons, may be used to address immune dysregulation associated with Aicardi Goutieres Syndrome. Nutritional support is also important, particularly if there are feeding difficulties or metabolic concerns. Additionally, genetic counseling provides valuable support for affected families, helping them understand the condition and its implications. Research into emerging treatments, such as targeted gene therapies and novel immunomodulatory agents, offers hope for more effective and personalized therapies in the future. A multidisciplinary approach involving neurologists, geneticists, and other specialists is essential to optimize care and meet the diverse needs of individuals with Aicardi Goutieres Syndrome.

Aicardi Goutieres Syndrome Epidemiology

As the Aicardi Goutieres Syndrome market is derived using the patient-based model, the Aicardi Goutieres Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Aicardi Goutieres Syndrome, Gender-specific Diagnosed Prevalent cases of Aicardi Goutieres Syndrome, Type-specific Cases of Aicardi Goutieres Syndrome in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034. As per DelveInsight's estimations, the total diagnosed prevalent cases of Aicardi Goutieres Syndrome in the 7MM was approximately 857 cases in 2023 and are projected to decrease during the forecast period.

• Among the 7MM, EU4 and the UK accounted for nearly 348 diagnosed prevalent cases of Aicardi Goutieres Syndrome, and these cases are expected to increase during the forecast period (2024-2034).
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of Aicardi Goutieres Syndrome, with 89 cases, followed by the UK and France in 2023. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2023.
• In Japan, there were around 98 diagnosed prevalent cases of Aicardi Goutieres Syndrome in 2023. These cases are expected to increase at a significant CAGR.
• Gender-specific diagnosed prevalent cases of Aicardi Goutieres Syndrome showed that males were more affected by Aicardi Goutieres Syndrome than females in the 7MM in 2023.

Aicardi Goutieres Syndrome Drug Chapters

The drug chapter segment of the Aicardi Goutieres Syndrome market report encloses a detailed analysis of Aicardi Goutieres Syndrome marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands Aicardi Goutieres Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Aicardi Goutieres Syndrome Emerging Drugs

TPN-101: Transposon Therapeutics, Inc.

TPN-101, developed by Transposon Therapeutics, Inc., is an emerging therapeutic candidate in the company's pursuit of innovative treatments for Aicardi-Goutieres Syndrome (Aicardi Goutieres Syndrome). This cutting-edge compound is a targeted, orally bioavailable small molecule designed to address the underlying genetic and immune system abnormalities associated with Aicardi Goutieres Syndrome. Preclinical research has highlighted TPN-101's potential to modulate critical biological pathways, reduce neuroinflammation, and improve neurological function. Currently in Phase II clinical trials, TPN-101 aims to offer a novel therapeutic option for Aicardi Goutieres Syndrome, a rare and challenging condition with limited effective treatments.

An open-label, Phase IIa study of TPN-101 in Aicardi Goutieres Syndrome patients is open for enrollment. Cohort 1, comprised of adult patients, has been completed. The study is recruiting patients aged 1 to 17 years to fill the remaining cohorts. The study is being conducted in France and Italy.

Aicardi Goutieres Syndrome Market Outlook

Aicardi-Goutieres Syndrome is a rare and complex genetic disorder that primarily impacts the neurological and immune systems. The treatment landscape for Aicardi Goutieres Syndrome is still developing, as the disorder's rarity and heterogeneity present significant challenges in establishing standardized treatment protocols. Currently, there are no universally approved treatments for Aicardi Goutieres Syndrome, and management typically focuses on symptomatic relief and supportive care.

Symptomatic treatment is the cornerstone of managing Aicardi Goutieres Syndrome. Given the diverse manifestations of the syndrome, which can include severe neurological impairments, seizures, and developmental delays, a multidisciplinary approach is essential. Neurological symptoms are often addressed with anticonvulsant medications to control seizures and muscle relaxants to alleviate spasticity. Developmental support through physical, occupational, and speech therapies is also crucial for addressing motor skills and communication challenges. These therapies aim to enhance quality of life and functional abilities, though they do not address the underlying genetic causes of the syndrome.

In addition to symptomatic management, some treatments focus on modulating the immune system. Aicardi Goutieres Syndrome is associated with autoimmunity and inflammatory responses, which can exacerbate symptoms and contribute to disease progression. Immunomodulatory therapies, including corticosteroids and other immunosuppressive agents, may be used to manage inflammatory symptoms and potentially improve overall health outcomes. However, these treatments are often aimed at managing symptoms rather than providing a cure or addressing the disease's root cause.

The field of Aicardi Goutieres Syndrome treatment is also seeing advancements through research and experimental therapies. Gene therapy represents a promising area of investigation, with the potential to target and correct the genetic mutations responsible for Aicardi Goutieres Syndrome. Although still largely in the experimental phase, such therapies could eventually offer a more direct approach to addressing the underlying genetic defects. Participation in clinical trials is another avenue for patients to access cutting-edge treatments and contribute to the advancement of scientific understanding.

Supportive care plays a vital role in the comprehensive management of Aicardi Goutieres Syndrome. This includes palliative care to address pain and improve quality of life, as well as genetic counseling to provide families with information about the genetic aspects of the syndrome and its implications. Support groups and patient advocacy organizations are also valuable resources, offering emotional support, practical advice, and information about ongoing research and treatment options.

Overall, the Aicardi Goutieres Syndrome treatment market is characterized by a combination of symptomatic management, experimental research, and supportive care. While no definitive cure exists, ongoing research and clinical trials offer hope for more targeted and effective treatments in the future. The collaborative efforts of healthcare professionals, researchers, and patient organizations are crucial in advancing treatment options and improving outcomes for individuals affected by this challenging condition.

The total Aicardi Goutieres Syndrome market size is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments.

Aicardi Goutieres Syndrome Drugs Uptake

This section focuses on the uptake rate of potential Aicardi Goutieres Syndrome drugs expected to launch in the market during 2020-2034. For example, TPN-101 in the US is expected to be launched by 2028.

Aicardi Goutieres Syndrome Pipeline Development Activities

The Aicardi Goutieres Syndrome market report provides insights into Aicardi Goutieres Syndrome clinicla trials within Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Aicardi Goutieres Syndrome market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Aicardi Goutieres Syndrome emerging therapies.

Aicardi Goutieres Syndrome KOL Views

To keep up with current Aicardi Goutieres Syndrome market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Aicardi Goutieres Syndrome evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Bambino Gesu Children's Hospital, Rome, Pediatric Hospital "Giannina Gaslini", Genoa, University Hospital Munich (LMU), Charite - Universitatsmedizin Berlin, University Hospital Heidelberg, Children's Hospital of Philadelphia, Boston Children's Hospital, Johns Hopkins Medicine, Stanford Children's Health and others.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Aicardi Goutieres Syndrome market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the Aicardi Goutieres Syndrome market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Aicardi Goutieres Syndrome Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global Aicardi Goutieres Syndrome drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The Aicardi Goutieres Syndrome market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Aicardi Goutieres Syndrome Market Report

• The Aicardi Goutieres Syndrome market report covers a segment of key events, an executive summary, descriptive overview of Aicardi Goutieres Syndrome, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging Aicardi Goutieres Syndrome therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Aicardi Goutieres Syndrome market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The Aicardi Goutieres Syndrome market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Aicardi Goutieres Syndrome market.

Aicardi Goutieres Syndrome Market Report Insights

• Aicardi Goutieres Syndrome Patient Population
• Aicardi Goutieres Syndrome Therapeutic Approaches
• Aicardi Goutieres Syndrome Pipeline Analysis
• Aicardi Goutieres Syndrome Market Size
• Aicardi Goutieres Syndrome Market Trends
• Existing and Future Aicardi Goutieres Syndrome Market Opportunity

Aicardi Goutieres Syndrome Market Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Aicardi Goutieres Syndrome Epidemiology Segmentation
• Key Cross Competition
• Attribute Analysis
• Aicardi Goutieres Syndrome Drugs Uptake
• Key Aicardi Goutieres Syndrome Market Forecast Assumptions

Aicardi Goutieres Syndrome Market Report Assessment

• Current Aicardi Goutieres Syndrome Treatment Practices
• Aicardi Goutieres Syndrome Unmet Needs
• Aicardi Goutieres Syndrome Pipeline Product Profiles
• Aicardi Goutieres Syndrome Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Aicardi Goutieres Syndrome Market Drivers
• Aicardi Goutieres Syndrome Market Barriers

Key Questions Answered In The Market Report

Aicardi Goutieres Syndrome Market Insights

• What was the Aicardi Goutieres Syndrome market size, the market size by therapies, and market share (%) distribution in 2020, and how would it all look in 2034? What are the contributing factors for this growth?
• What unmet needs are associated with the current treatment Aicardi Goutieres Syndrome market?
• What are the patents of emerging therapies for Aicardi Goutieres Syndrome?
• Which drug is going to be the largest contributor by 2034?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the Aicardi Goutieres Syndrome market dynamics and subsequent analysis of the associated trends?

Aicardi Goutieres Syndrome Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Aicardi Goutieres Syndrome? What will be the growth opportunities across the 7MM concerning the patient population of Aicardi Goutieres Syndrome?
• What is the historical and forecasted Aicardi Goutieres Syndrome patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which country is more prevalent for Aicardi Goutieres Syndrome and why?
• What factors are affecting the diagnosis of the indication?

Current Aicardi Goutieres Syndrome Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for treating Aicardi Goutieres Syndrome? What are the current guidelines for treating Aicardi Goutieres Syndrome in the US and Europe?
• How many Aicardi Goutieres Syndrome companies are developing therapies for treating Aicardi Goutieres Syndrome?
• How many emerging therapies are in the mid-stage and late stage of development for treating Aicardi Goutieres Syndrome?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the key designations that have been granted for the emerging therapies for Aicardi Goutieres Syndrome?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved Aicardi Goutieres Syndrome therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted Aicardi Goutieres Syndrome market?

Reasons to Buy Aicardi Goutieres Syndrome Market Report

• The Aicardi Goutieres Syndrome market report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Aicardi Goutieres Syndrome Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing Aicardi Goutieres Syndrome market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current Aicardi Goutieres Syndrome patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the Aicardi Goutieres Syndrome market will help devise strategies that will help get ahead of competitors.
• Detailed analysis and ranking of potential current and emerging Aicardi Goutieres Syndrome therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Aicardi Goutieres Syndrome market so that the upcoming Aicardi Goutieres Syndrome companies can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What is the forecast period covered in the report?

The Aicardi Goutieres Syndrome Epidemiology and Market Insight report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key players in the Aicardi Goutieres Syndrome market?

The Aicardi Goutieres Syndrome market is sparse. The major players are Transposon Therapeutics, Inc which are currently developing drugs for the treatment of Aicardi Goutieres Syndrome, the rest of the market is now contributed with off-label therapies.

3. How is the market size estimated in the forecast report?

The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the Aicardi Goutieres Syndrome market?

The increase in prevalent and diagnosed prevalent cases of Aicardi Goutieres Syndrome is attributed to the current population size.

5. What is the expected impact of emerging therapies or advancements in Aicardi Goutieres Syndrome treatment on the market?

Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Aicardi Goutieres Syndrome treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?

The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Aicardi Goutieres Syndrome market.

Table of Contents

1 Key Insights

2 Report Introduction

3 Aicardi Goutieres Syndrome Market Share Distribution by Therapies

• 3.1 Market Share (%) Distribution of AGS in 2020
• 3.2 Market Share (%) Distribution of AGS in 2034

4 Methodology of AGS Epidemiology and Market

5 Executive Summary of AGS

6 Key Events

7 Disease Background and Overview: AGS

• 7.1 Introduction
• 7.2 Stages of AGS
• 7.3 Pathophysiology of AGS
• 7.4 Pathogenesis of AGS
• 7.5 Causes and Risk Factors of AGS
• 7.6 Symptoms of Aicardi Goutieres Syndrome
• 7.7 Aicardi Goutieres Syndrome Diagnosis
  • 7.7.1 Diagnostic Algorithm
  • 7.7.2 Diagnostic Guidelines
• 7.8 Aicardi Goutieres Syndrome Treatment
  • 7.8.1 Treatment Algorithm
  • 7.8.2 Treatment Guidelines

8 Epidemiology and Patient Population

• 8.1 Key Finding
• 8.2 Assumption and Rationale: 7MM
  • 8.2.1 Total Diagnosed Prevalent Cases of AGS
  • 8.2.2 Gender-specific Diagnosed Prevalent Cases of AGS
  • 8.2.3 Type-specific Diagnosed Prevalent Cases of AGS
• 8.3 The United States
  • 8.3.1 Total Diagnosed Prevalent Cases of AGS in the US
  • 8.3.2 Gender-specific Diagnosed Prevalent Cases of AGS in the US
  • 8.3.3 Type-specific Diagnosed Prevalent Cases of AGS in the US
• 8.4 EU4 and the UK
  • 8.4.1 Germany
    • 8.4.1.1 Total Diagnosed Prevalent Cases of AGS in Germany
    • 8.4.1.2 Gender-specific Diagnosed Prevalent Cases of AGS in Germany
    • 8.4.1.3 Type-specific Diagnosed Prevalent Cases of AGS in Germany
  • 8.4.2 France
    • 8.4.2.2 Total Diagnosed Prevalent Cases of AGS in France
    • 8.4.2.3 Gender-specific Diagnosed Prevalent Cases of AGS in France
    • 8.4.2.4 Type-specific Diagnosed Prevalent Cases of AGS in France
  • 8.4.3 Italy
    • 8.4.3.2 Total Diagnosed Prevalent Cases of AGS in Italy
    • 8.4.3.3 Gender-specific Diagnosed Prevalent Cases of AGS in Italy
    • 8.4.3.4 Type-specific Diagnosed Prevalent Cases of AGS in Italy
  • 8.4.4 Spain
    • 8.4.4.2 Total Diagnosed Prevalent Cases of AGS in Spain
    • 8.4.4.3 Gender-specific Diagnosed Prevalent Cases of AGS in Spain
    • 8.4.4.4 Type-specific Diagnosed Prevalent Cases of AGS in Spain
  • 8.4.5 The UK
    • 8.4.5.2 Total Diagnosed Prevalent Cases of AGS in The UK
    • 8.4.5.3 Gender-specific Diagnosed Prevalent Cases of AGS in The UK
    • 8.4.5.4 Type-specific Diagnosed Prevalent Cases of AGS in The UK
• 8.5 Japan
  • 8.5.2 Total Diagnosed Prevalent Cases of AGS in Japan
  • 8.5.3 Gender-specific Diagnosed Prevalent Cases of AGS in Japan
  • 8.5.4 Type-specific Diagnosed Prevalent Cases of AGS in Japan

9 Aicardi Goutieres Syndrome Patient Journey

10 Aicardi Goutieres Syndrome Emerging Drug

• 10.1 Key Cross
• 10.2 TPN-101: Transposon Therapeutics, Inc.
  • 10.2.1 Product Description
  • 10.2.2 Other Developmental Activities
  • 10.2.3 Clinical Trials Information
  • 10.2.4 Safety and Efficacy
  • 10.2.5 Analysts' Views

11 Aicardi Goutieres Syndrome Market Analysis

• 11.1 Key Findings
• 11.2 Aicardi Goutieres Syndrome Market Outlook
• 11.3 Conjoint Analysis
• 11.4 Key Market Forecast Assumptions
• 11.5 Total Market Size of AGS in the 7MM
• 11.6 Market Size of AGS by Therapies in the 7MM
• 11.7 Market Size of AGS in the United States
  • 11.7.1 Total Market Size of AGS
  • 11.7.2 Market Size of AGS by Therapies in the United States
• 11.8 Market Size of AGS in EU4 and the UK
  • 11.8.1 Market Size of AGS in Germany
    • 11.8.1.1 Total Market Size of AGS
    • 11.8.1.2 Market Size of AGS by Therapies in Germany
  • 11.8.2 Market Size of AGS in France
    • 11.8.2.1 Total Market Size of AGS
    • 11.8.2.2 Market Size of AGS by Therapies in France
  • 11.8.3 Market Size of AGS in Italy
    • 11.8.3.1 Total Market Size of AGS
    • 11.8.3.2 Market Size of AGS by Therapies in Italy
  • 11.8.4 Aicardi Goutieres Syndrome Market Size in Spain
    • 11.8.4.1 Total Aicardi Goutieres Syndrome Market Size
    • 11.8.4.2 Aicardi Goutieres Syndrome Market Size by Therapies in Spain
  • 11.8.5 Market Size of AGS in the UK
    • 11.8.5.1 Total Aicardi Goutieres Syndrome Market Size
    • 11.8.5.2 Aicardi Goutieres Syndrome Market Size by Therapies in the UK
• 11.9 Aicardi Goutieres Syndrome Market Size in Japan
  • 11.9.1 Total Aicardi Goutieres Syndrome Market Size
  • 11.9.2 Aicardi Goutieres Syndrome Market Size by Therapies in Japan

12 Key Opinion Leaders' Views

13 Aicardi Goutieres Syndrome SWOT Analysis

14 Aicardi Goutieres Syndrome Unmet Needs

15 Aicardi Goutieres Syndrome Market Access and Reimbursement

• 15.1 The United States
  • 15.1.1 Centre for Medicare and Medicaid Services (CMS)
• 15.2 In EU4 and the UK
  • 15.2.1 Germany
  • 15.2.2 France
  • 15.2.3 Italy
  • 15.2.4 Spain
  • 15.2.5 The United Kingdom
• 15.3 Japan
  • 15.3.1 MHLW

16 Appendix

• 16.1 Bibliography
• 16.2 Acronyms and Abbreviations

17 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer